2022
Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study.
Giri V, Gross L, Russo J, Shimada A, McNair C, Kelly W, Gomella L. Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study. Journal Of Clinical Oncology 2022, 40: 188-188. DOI: 10.1200/jco.2022.40.6_suppl.188.Peer-Reviewed Original ResearchProstate cancerPrevalence of FAGermline testingEMPOWER studyMultigene testingMutation carriersMutation prevalencePopulation prevalenceExact testLimited prevalence dataGene mutationsLikely pathogenic mutationsFisher's exact testCancer risk genesClinical characteristicsGleason scoreMean ageClinical trialsPCa diagnosisFA genesFas gene mutationPrevalence ratesCancer managementPCa biologyFA pathway genes
2021
Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine.
Giri V, Shimada A, Leader A. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precision Oncology 2021, 5: 1699-1708. PMID: 34778693, PMCID: PMC8585288, DOI: 10.1200/po.21.00231.Peer-Reviewed Original ResearchConceptsExact testCancer informationMultivariate logistic regression modelPopulation-based studyCross-sectional studyFisher's exact testPopulation-based sampleGenetic awarenessNational Trends SurveyNon-Hispanic whitesLogistic regression modelsPrecision medicine eraMiddle-high incomeDiverse population-based sampleCancer careModifiable factorsPersonalized cancer treatmentCancer preventionFemale genderHealth literacyCancer fatalismMedical literacyMultivariate analysisEthnic disparitiesGenetic testing
2019
Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men
Chandrasekar T, Gross L, Gomella L, Hegarty S, Leong J, Giri V. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. European Urology Oncology 2019, 3: 291-297. PMID: 31278035, DOI: 10.1016/j.euo.2019.06.010.Peer-Reviewed Original ResearchConceptsHereditary cancer syndromesProstate cancerCancer syndromesFamily historyGermline mutationsExact testHereditary breastGenetic testingAfrican AmericansPCa family historyAfrican American patientsOvarian cancer syndromeCascade genetic testingFisher's exact testHereditary prostate cancerBRCA mutationsLynch syndromeOvarian cancerSyndromeCancerCascade testingDiverse cohortAA participantsSpectrum of genesFHx
2018
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
Giri V, Hegarty S, Hyatt C, O'Leary E, Garcia J, Knudsen K, Kelly W, Gomella L. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate 2018, 79: 333-339. PMID: 30450585, DOI: 10.1002/pros.23739.Peer-Reviewed Original ResearchConceptsBreast cancer family historyCancer family historyProstate cancerFamily historyMetastatic diseaseGleason scoreExact testGenetic testingRetrospective cross-sectional analysisDNA repair genesCurrent NCCN guidelinesInherited prostate cancerGermline genetic testingHigh Gleason scoreFisher's exact testIdentification of menRepair genesPathogenic variant spectrumCross-sectional analysisFamily history dataGenetic testing capabilitiesNCCN guidelinesTherapeutic managementMultigene testingPV rates
2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers